A Single Arm Pilot Study of Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma
Status: Withdrawn prior to enrolment
Phase of Trial: Phase 0
Latest Information Update: 16 Jan 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Therapeutic Use
- 13 Mar 2018 Status changed from not yet recruiting to withdrawn prior to enrolment as the company pulled durvalumab from heme malignancies
- 15 Jan 2018 Planned initiation date changed from 1 Jan 2018 to 1 Mar 2018.
- 13 Nov 2017 Planned initiation date changed from 1 Nov 2017 to 1 Jan 2018.